Skip to content
Medical Health Aged Care

ACN Foundation partnership with Endometriosis Australia

Australian College of Nursing Foundation 2 mins read

MEDIA RELEASE

12 May 2024

ACN Foundation partnership with Endometriosis Australia

International Nurses Day 2024

 

The Australian College of Nursing (ACN) Foundation is proud to be part of an important partnership with Endometriosis Australia to train Endometriosis Specialty Nurses (Endo Nurses) to provide much-needed care in communities in rural, remote, and regional Australia.

 

The new scholarship program will fund training for 100 Endo Nurses to provide high-quality care in communities with limited access to the full range of healthcare facilities and services, including specialised endometriosis care and advice, available to other Australians.

 

The scholarships – valued at $2,900 each – will be funded by Endometriosis Australia as part of its ongoing Endo Academy campaign.

 

Applications will be accepted from 1 September 2024, successful applicants announced on 1 December 2024, with the first intake commencing training in January 2025.

 

Interim ACN CEO, Emeritus Professor Leanne Boyd, said nurses provide quality care and support for those with endometriosis. 

 

Professor Boyd said nurses care for patients with endometriosis in many settings, including emergency departments, schools, medical or surgical wards, perioperative care, mental health facilities, and fertility services. 

 

"In many rural areas where there is no GP or local hospital, the nurse is the main or sole healthcare professional in the community. They are well placed to assist with early recognition, advice, and treatment for people with endometriosis.

 

“It is a great honour to work closely with Endometriosis Australia on this important initiative," Professor Boyd said.

 

During the 10-week unit of study, nurses will be empowered with the knowledge and essential attributes to be advocates for all individuals experiencing chronic pelvic pain and endometriosis. 

 

This unit of study provides the students with the necessary theoretical knowledge to improve how they assess and manage endometriosis and pelvic pain in the clinical setting.

This is achieved by exploring endometriosis pathophysiology, pain physiology, and contemporary, evidence-based treatment and management within various clinical settings. 

 

A holistic, individual, person-centred approach is core to this unit. 

 

You can learn more about Endometriosis Australia and the scholarship program and donate to Endometriosis Australia here https://endometriosisaustralia.org/

 

You can learn more about the ACN Foundation here https://foundation.acn.edu.au/

 

For more information:

ACN
John Flannery 0419 494 761
Email: acn.media@acn.edu.au

 

Endometriosis Australia

Lucinda Mirabello, HAVAS Red, 0432 597 768

Email: lucinda.mirabello@havasred.com

 

ACN Social media channels:

Facebook: https://www.facebook.com/acnursing

X(Twitter): https://twitter.com/acn_tweet

LinkedIn: http://www.linkedin.com/company/australian-college-of-nursing

Instagram: https://www.instagram.com/acn_nursing

 

 

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Education Training, Medical Health Aged Care
  • 31/10/2024
  • 11:30
UNSW Sydney

Record donation awarded to UNSW Sydney will enable the Kirby Institute and partners to advance cervical cancer elimination in the Pacific

Media Release 01.00AM AEDT, Friday 1 November 2024 Record donation awarded to UNSW Sydney will enable the Kirby Institute and partners to advance cervical cancer elimination in the Pacific A $25.9 million donation from the Swire Group will support cervical cancer screening and treatment for over 130,000 women in seven Pacific countries. UNSW Sydney has received the largest single philanthropic donation in its history to work with regional partners to tackle one of the deadliest preventable cancers in the Pacific. The $25.9 million donation from the Swire Group will enable UNSW’s Kirby Institute to work with partners in Australia and…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.